Correct me if I'm wrong, but isn't the primary endpoint for m2m trials how many of the drugged group move on to become severe/critical? If leronlimab's MOA is as advertised and works as Dr. P has explained (and confirmed with data), then the expected result should be that at least 2/3 of the patients did not progress to s/c (and are either still in the hospital recovering or have gotten better and went home).

If all or most of the placebo progressed to s/c, then it would be obvious that leronlimab is effective. If all or most of the placebo instead got better, then I'd say FDA will require a ph3 trial. So I feel guilty in stating that I hope the former for the placebo group. But I also hope they got moved into the s/c trial and received leronlimab then.

But I digressed. My point was that there is a strong possibility that the government will tout leronlimab as a theraputic later this week since the end point for the m2m trial should be quick and easily deciphered from the data. Almost anecdotal except with an unidentified placebo group.